Genmab A/S (NASDAQ:GMAB) Releases Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Genmab A/S (NASDAQ:GMAB) announced its earnings results on Thursday. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.36 by $0.20, Zacks reports. The company had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.20 billion. Genmab A/S had a return on equity of 13.96% and a net margin of 16.97%.

Here are the key takeaways from Genmab A/S’s conference call:

• Genmab reported 22% revenue growth for the first nine months of 2026 and 9% growth in adjusted operating profit. Management said growth is becoming more diversified, with roughly half of revenue growth coming from outside DARZALEX.
• Commercial momentum continued: EPKINLY sales rose 47% to $491 million, while TIVDAK sales increased 9% to $131 million. Genmab highlighted broader EPKINLY adoption and continued TIVDAK growth in Japan and Europe.
• The company announced three positive Phase III readouts in October: EPKINLY in frontline DLBCL, Rina-S in platinum-resistant ovarian cancer, and petosemtamab in first-line head and neck cancer. Genmab sees potential launches beginning in 2027, though the medicines remain subject to regulatory review.
• Genmab maintained its 2026 guidance, expects revenue in the upper part of its $4.325–$4.525 billion range, and said adjusted operating profit should finish above the midpoint of its guidance range.
• Management cautioned that fourth-quarter operating expenses will rise significantly due to manufacturing, clinical development, and launch-readiness work for Rina-S and petosemtamab.

Genmab A/S Price Performance

Genmab A/S stock traded up $0.89 during midday trading on Friday, reaching $53.63. The company’s stock had a trading volume of 7,827,783 shares, compared to its average volume of 6,032,240. Genmab A/S has a 52 week low of $23.62 and a 52 week high of $59.97. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81. The business has a 50-day moving average price of $39.18 and a 200-day moving average price of $31.11. The stock has a market cap of $33.47 billion, a PE ratio of 45.84, a price-to-earnings-growth ratio of 2.11 and a beta of 0.73.

Analysts Set New Price Targets

Several research firms have weighed in on GMAB. HC Wainwright increased their price objective on Genmab A/S from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. Weiss Ratings upgraded shares of Genmab A/S from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, September 1st. Morgan Stanley raised their target price on shares of Genmab A/S from $42.00 to $57.00 and gave the company an “equal weight” rating in a report on Friday, October 30th. Truist Financial restated a “buy” rating and issued a $67.00 target price (up from $45.00) on shares of Genmab A/S in a research report on Thursday, October 29th. Finally, New Street Research set a $43.00 price target on shares of Genmab A/S in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $53.61.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company founded in 1999 and headquartered in Copenhagen, Denmark. It discovers and develops antibody-based medicines, with a focus on cancer and other serious diseases.

The company develops treatments independently and with pharmaceutical partners. Its collaborations have resulted in medicines including daratumumab (Darzalex), developed with Johnson & Johnson, and epcoritamab (Epkinly), developed with AbbVie. Genmab also advances a pipeline of antibody-based therapies and uses proprietary technologies to design and engineer therapeutic antibodies.

Genmab operates internationally, with activities across Europe, North America and Asia.